Companies: 10,795·Total market cap: $144.5T
Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc.

CLDIAMEXHealthcare● Active
$0.17
+$0.00(+2.78%)
Market Cap$1279647
P/E Ratio
52W High$19.2
52W Low$0.16
SEC Filings

Calidi Biotherapeutics, Inc. (CLDI) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001855485 · CLDI · AMEX · as of Jun 8, 2026

Filing snapshot

387
Total Filings
DEFA14A
Latest Form
2026-06-05
Most Recent
2021
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001855485 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-27
Fiscal Year End
Mar 27, 2026
Accession No.
0001493152-26-013242
Primary Document
form10-k.htm
Source: data.sec.gov · CIK 0001855485 · Accession 0001493152-26-013242

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-14
8-KCurrent Report
8-K
2026-05-29Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
DEFA14AProxy Statement (Additional)
DEFA14A
2026-06-05
View
8-KCurrent Report
8-K
2026-05-29
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-14
View
8-KCurrent Report
8-K
2026-05-14
View
8-KCurrent Report
8-K
2026-05-08
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-29
View
DEF 14AProxy Statement
DEF 14A
2026-04-29
View
PRE 14APRE 14A
PRE 14A
2026-04-17
View
8-KCurrent Report
8-K
2026-04-02
View
SCHEDULE 13DSCHEDULE 13D
SCHEDULE 13D
2026-03-31
View
10-KAnnual Report
10-K
2026-03-27
View
8-KCurrent Report
8-K
2026-03-27
View
8-KCurrent Report
8-K
2026-03-11
View
SCHEDULE 13DSCHEDULE 13D
SCHEDULE 13D
2026-03-09
View
Showing 1–15 of 341 filingsForm 4 / 144 hidden· 387 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001855485  |  Exchange: AMEX · Healthcare

Calidi Biotherapeutics, Inc. (AMEX: CLDI) has submitted 387 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001855485, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Calidi Biotherapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Calidi Biotherapeutics, Inc. 10-K was filed on 2026-03-27 for fiscal year ending 2026. Historical CLDI 10-K annual reports are available from 2021 through 2026.

Investors researching Calidi Biotherapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

CLDI SEC Filings · 8 questions

Calidi Biotherapeutics, Inc. (CLDI) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 387 filings and access original documents at no cost. Calidi Biotherapeutics, Inc.'s CIK is 0001855485.

CLDI SEC filingsCalidi Biotherapeutics, Inc. SEC documentsfind CLDI 10-K